BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 17589339)

  • 1. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
    Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that ursodeoxycholic acid prevents steroid-resistant rejection in adult liver transplantation.
    Clavien PA; Sharara AI; Camargo CA; Harland RC; Fitz JG
    Clin Transplant; 1996 Dec; 10(6 Pt 2):658-62. PubMed ID: 8996761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.
    Barnes D; Talenti D; Cammell G; Goormastic M; Farquhar L; Henderson M; Vogt D; Mayes J; Westveer MK; Carey W
    Hepatology; 1997 Oct; 26(4):853-7. PubMed ID: 9328304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT
    Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection.
    Bährle S; Szabó G; Stiehl A; Theilmann L; Dengler TJ; Zimmermann R; Kübler W
    J Heart Lung Transplant; 1998 Jun; 17(6):592-8. PubMed ID: 9662095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients.
    Assy N; Adams PC; Myers P; Simon V; Ghent CN
    Gut; 2007 Feb; 56(2):304-6. PubMed ID: 17303606
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience.
    Toyoki Y; Hakamada K; Narumi S; Totsuka E; Nara M; Ono H; Ishizawa Y; Sasaki M
    Transplant Proc; 2004 Oct; 36(8):2279-81. PubMed ID: 15561218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of immunosuppression withdrawal after liver transplantation.
    Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND
    Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
    Tisone G; Orlando G; Cardillo A; Palmieri G; Manzia TM; Baiocchi L; Lionetti R; Anselmo A; Toti L; Angelico M
    J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
    Jorgensen R; Angulo P; Dickson ER; Lindor KD
    Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients.
    Jacob DA; Neumann UP; Bahra M; Klupp J; Puhl G; Neuhaus R; Langrehr JM
    Clin Transplant; 2006; 20(2):211-20. PubMed ID: 16640529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.